DeepMed Research

The Emmes Company, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Mitochondrial Video Assessment Source Material Study

Completed

Conditions: PolG, Primary Mitochondrial Myopathy

First Posted Date: 2023-12-22

Last Posted Date: 2024-11-14

Lead Sponsor: The Emmes Company, LLC

Target Recruit Count: 28

Registration Number: NCT06180421

Locations: 🇺🇸
Casimir, Kingston, Massachusetts, United States

Duchenne Muscular Dystrophy Video Assessment Registry

Active, not recruiting

Conditions: Duchenne Muscular Dystrophy

First Posted Date: 2023-02-03

Last Posted Date: 2024-11-14

Lead Sponsor: The Emmes Company, LLC

Target Recruit Count: 180

Registration Number: NCT05712447

Locations: 🇺🇸
Emmes, Rockville, Maryland, United States

Angelman Syndrome Video Assessment (ASVA) Source Material Study

Completed

Conditions: Angelman Syndrome

First Posted Date: 2022-12-05

Last Posted Date: 2023-12-13

Lead Sponsor: The Emmes Company, LLC

Target Recruit Count: 73

Registration Number: NCT05637697

Locations: 🇺🇸
Casimir, Kingston, Massachusetts, United States

Limb-Girdle Video Assessment

Terminated

Conditions: Limb-Girdle Muscular Dystrophy ; Subtypes 2A, 2B, and 2I

First Posted Date: 2022-09-06

Last Posted Date: 2023-12-18

Lead Sponsor: The Emmes Company, LLC

Target Recruit Count: 45

Registration Number: NCT05528757

Locations: 🇺🇸
Casimir, Kingston, Massachusetts, United States

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

Phase 1

Completed

Conditions: Central Retinal Vein Occlusion

Interventions: Biological: Autologous Bone Marrow CD34+ Stem Cells
Biological: Sham Therapy

First Posted Date: 2019-06-11

Last Posted Date: 2024-12-02

Lead Sponsor: The Emmes Company, LLC

Target Recruit Count: 16

Registration Number: NCT03981549

Locations: 🇺🇸
Department of Ophthalmology & Vision Science, University of California Davis Eye Center, Sacramento, California, United States

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

Phase 3

Completed

Conditions: Central Retinal Vein Occlusion

Interventions: Drug: aflibercept
Drug: bevacizumab

First Posted Date: 2013-10-25

Last Posted Date: 2021-06-22

Lead Sponsor: The Emmes Company, LLC

Target Recruit Count: 362

Registration Number: NCT01969708

Locations: 🇺🇸
Emory University Eye Center, Atlanta, Georgia, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
Illinois Eye and Ear Infirmary UIC Dept. of Ophthalmology, Chicago, Illinois, United States

and more 63 locations

Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections

Phase 1

Completed

Conditions: Intra-abdominal Infection
Necrotizing Enterocolitis

Interventions: Drug: meropenem

First Posted Date: 2008-02-22

Last Posted Date: 2023-04-25

Lead Sponsor: The Emmes Company, LLC

Target Recruit Count: 200

Registration Number: NCT00621192

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Magee Women's Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

and more 23 locations

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

Phase 2

Terminated

Conditions: Leukemia, Myeloid, Chronic
Anemia, Aplastic
Myelofibrosis
Lymphoma
Hodgkin Disease
Leukemia, Lymphocytic, Chronic
Leukemia, Myelocytic, Acute
Leukemia, Lymphocytic, Acute

Interventions: Drug: Parathyroid Hormone (teriparatide)

First Posted Date: 2006-10-27

Last Posted Date: 2013-04-29

Lead Sponsor: The Emmes Company, LLC

Target Recruit Count: 13

Registration Number: NCT00393380

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Dose-response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room

Phase 2

Completed

Conditions: Hypotension

Interventions: Drug: Nitroprusside

First Posted Date: 2005-08-26

Last Posted Date: 2024-01-02

Lead Sponsor: The Emmes Company, LLC

Target Recruit Count: 211

Registration Number: NCT00135668

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Lorazepam Sedation for Critically Ill Children

Phase 2

Completed

Conditions: Critical Illness

Interventions: Drug: Lorazepam CI
Drug: Lorazepam
Drug: Midazolam

First Posted Date: 2005-04-28

Last Posted Date: 2023-03-20

Lead Sponsor: The Emmes Company, LLC

Target Recruit Count: 179

Registration Number: NCT00109395

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy